Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjögren-Larsson syndrome

Archives of Dermatological Research

Volumn 296, Issue 12, 2005, Pages 568-572

  Haug, Stefanie ^a   Braun Falco, Markus ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

AAV; Cutaneous gene therapy; FALDH; Genodermatosis; Ichthyosis

Indexed keywords

ADENOVIRUS VECTOR; ALDEHYDE; ALDEHYDE DEHYDROGENASE; ALIPHATIC CARBOXYLIC ACID; COMPLEMENTARY DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDOREDUCTASE;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ARTICLE; CELL LINE; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE THERAPY; GENE VECTOR; HAMSTER; ICHTHYOSIS; MENTAL DEFICIENCY; MOEBIUS SYNDROME; NONHUMAN; OXIDATION; PRIORITY JOURNAL; SJOEGREN LARSSON SYNDROME; SPASTICITY; SYMPTOM;

ALDEHYDE OXIDOREDUCTASES; ANIMALS; CHO CELLS; CRICETINAE; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; SJOGREN-LARSSON SYNDROME;

EID: 20944443123     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-005-0556-x     Document Type: Article

References (17)

1. Braun-Falco M, Doenecke A, Smola H, Hallek M (1999) Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Therapy 6:432-441
2. Braun-Falco M, Eisenried A, Büning H, Ring J (2005) Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both ubiquitin/proteasome pathway and epidermal growth factor-receptor tyrosine kinase. Arch Dermatol Res 296:528-535
3. Büning H, Braun-Falco M, Hallek M (2004) Progress in the use of adeno-associated virus vectors for gene therapy. Cells Tis Org 177:139-150
4. De Laurenzi V, Rogers GR, Hamrock DJ, Marekov LN, Steinert PM, Compton JG, Markova N, Rizzo WB (1996) Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nature Genetics 12:52-57
5. James PF, Zoeller RA (1997) Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase. J Biol Chem 272:23532-23539
6. Kelson TL, Craft DA, Rizzo WB (1992) Carrier detection for Sjögren-Larsson syndrome. J Inherited Metab Dis 15:105-111
7. Kelson TL, Secor McVoy JR, Rizzo WB (1997) Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Biochimica et Biophysica Acta 1335:99-110
8. Möhrenschlager M, Rizzo WB, Kraus CS, Limbrock J, Cohen M, Anton-Lamprecht I, Abeck D, Ring J (2000) Sjögren-Larsson-Syndrom. Hautarzt 51:250-255
9. Rizzo WB, Craft DA (1991) Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblast. J Clin Invest 88:1643-1648
10. Rizzo WB (1993) Sjögren-Larsson Syndrome. Sem Dermatol 12:210-218
11. Rizzo WB, Carney G, Lin Z (1999) The molecular basis of Sjögren-Larsson syndrome: Mutation analysis of Fatty Aldehyde Dehydrogenase Gene. Am J Hum Genet 65:1547-1560
12. Rizzo WB, Heinz E, Simo M, Craft DA (2000) Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implication for Sjögren-Larsson syndrome. Biochimica Biophysica Acta 1535:1-9
13. Sanlioglu S, Monick MM, Luleci G, Hunninghake GW, Engelhardt JF (2001) Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther 1:137-147
14. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
15. Willemsen MA, Lutt MA, Steijlen PM, Cruysberg JR, van der Graaf M, Nijhuis-van der Sanden MW, Pasman JW, Mayatepek E, Rotteveel JJ (2001) Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr 160:711-717
16. Xiao X, Li J, Samulski RJ (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovims. J Virol 72:2224-2232
17. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6:973-985